The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.
Head and Neck Cancer, Lung Cancer
The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.
ATATcH Alternating Treatment Plans for Advanced Cancer
-
Trinitas Hospital and Comprehensive Cancer Center, Elizabeth, New Jersey, United States, 07207
Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States, 08690
RWJBarnabas Health - Jersey City, Jersey City, New Jersey, United States, 07304
RWJBarnabas Health - Monmouth Medical Center Southern Campus, Lakewood, New Jersey, United States, 08701
RWJBarnabas Health - Saint Barnabas Medical Center, Livingston, New Jersey, United States, 10457
RWJBarnabas Health - Monmouth Medical Center, Long Branch, New Jersey, United States, 07740
RWJ Barnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States, 08901
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States, 08903
RWJBarnabas Health - Newark Beth Israel Medical Center, Newark, New Jersey, United States, 07112
Robert Wood Johnson Somerset Hospital, Somerville, New Jersey, United States, 08876
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Rutgers, The State University of New Jersey,
Missak Haigentz, MD, PRINCIPAL_INVESTIGATOR, Rutgers Cancer Institute of New Jersey
2025-12-01